Patents Assigned to Thermo Fisher Scientific Biosciences Inc.
  • Publication number: 20140213639
    Abstract: Lentiviral vectors, plates, kits and methods are provided that permit improved efficiency for selection of a promoter sequence for use in a lentiviral application. Through various embodiments of the present invention, a researcher may first evaluate and then choose in a modular fashion, a vector comprising a promoter that is effective for expression in a particular cell line or type.
    Type: Application
    Filed: October 2, 2012
    Publication date: July 31, 2014
    Applicant: THERMO FISHER SCIENTIFIC BIOSCIENCES INC.
    Inventor: John Wakefield
  • Publication number: 20140193914
    Abstract: Methods and kits for lentiviral production are provided. By separating certain components of the vector including but not limited to promoter, reporter and selection marker preference components from the genetic content of interest, one can create libraries that allow for the efficient generation of custom selected lentiviral vectors.
    Type: Application
    Filed: September 13, 2012
    Publication date: July 10, 2014
    Applicant: THERMO FISHER SCIENTIFIC BIOSCIENCES INC.
    Inventors: Jamie Cearley, Rusla DuBreuil
  • Publication number: 20140148362
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.
    Type: Application
    Filed: December 5, 2013
    Publication date: May 29, 2014
    Applicant: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Publication number: 20140094390
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 3, 2014
    Applicant: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Publication number: 20140066595
    Abstract: Cell-free extracts, methods for producing these extracts, methods for using these extracts, compositions that facilitate production of these extracts and kits that contain these extracts are provided. By increasing or decreasing certain gene products through, for example, the use of siRNA or mimics, one can develop mammalian cell-free extracts that have desired levels of efficiency.
    Type: Application
    Filed: August 26, 2013
    Publication date: March 6, 2014
    Applicant: THERMO FISHER SCIENTIFIC BIOSCIENCES INC.
    Inventors: Emily Anderson, Peter Bell, Penny Jensen, Jon Karpilow, Anja Smith, Krishna Vattem, Brian Webb, Devin Leake, Alex Medford, Elena Maksimova, Craig Smith
  • Patent number: 8658784
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APP.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: February 25, 2014
    Assignee: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8658785
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: February 25, 2014
    Assignee: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read
  • Publication number: 20140031414
    Abstract: Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.
    Type: Application
    Filed: August 27, 2013
    Publication date: January 30, 2014
    Applicants: ALCON RESEARCH, LTD., THERMO FISHER SCIENTIFIC BIOSCIENCES INC.
    Inventors: Anja Smith, Angela Reynolds, Jon E. Chatterton, Xinyu Zhang
  • Patent number: 8633306
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: January 21, 2014
    Assignee: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8580757
    Abstract: The present disclosure includes compositions and methods for modulating the differentiation of cells having osteogenic differentiation potential (such as mesenchymal stem cells (MSCs)) towards the osteogenic fate, and for obtaining diagnostic and prognostic information relating to diseases and disorders characterized by defects in osteogenic differentiation. The compositions include miRNAs, rm?RNA mimics, miRNA inhibitors, and siRNAs.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: November 12, 2013
    Assignee: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Yuriy Federov, Devin Leake
  • Patent number: 8575329
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: November 5, 2013
    Assignee: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8546349
    Abstract: Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: October 1, 2013
    Assignees: Thermo Fisher Scientific Biosciences Inc., Alcon Research, Ltd.
    Inventors: Anja Smith, Angela Reynolds, Jon E. Chatterton, Xinyu Zhang